Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes-Reference-Cited by-同舟云学术

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

Published:2005-01 Issue:2 Volume:128 Page:204-209
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Musto Pellegrino,Lanza Francesco,Balleari Enrico,Grossi Alberto,Falcone Antonietta,Sanpaolo Grazia,Bodenizza Carlo,Scalzulli Potito Rosario,Sala Antonio La,Campioni Diana,Ghio Riccardo,Cascavilla Nicola,Carella Angelo Michele

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2004.05288.x/fullpdf

Reference28 articles.

1. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

2. Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin

3. Control of cancer-related anemia with erythropoietic agents:a review of evidence for improved quality of life and clinical outcomes

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes;Journal of Clinical Medicine;2024-05-04

2. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: A nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy;2023-12-21

3. Lower‐risk myelodysplastic syndromes: Current treatment options for anemia;eJHaem;2022-08-12

4. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options;Cancer Management and Research;2021-01

5. JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-6 myelodysplastic syndromes (MDS);International Journal of Hematology;2020-02-14